Antibiotic treatment interruption of suspected lower respiratory tract infections based on a single procalcitonin measurement at hospital admission - A randomized trial

Clinical Microbiology and Infection

Volumn 15, Issue 5, 2009, Pages 481-487

  Kristoffersen, K B ^a   Sogaard O S ^a   Wejse, C ^a   Black, F T ^a   Greve, T ^b   Tarp, B ^b   Storgaard, M ^c   Sodemann, M ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b SILKEBORG REGIONAL HOSPITAL   (Denmark)

^c RANDERS REGIONAL HOSPITAL   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Antibiotic use; Community acquired pneumonia; Controlled trial; COPD; Procalcitonin

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; TREATMENT DURATION;

BACTERIA (MICROORGANISMS);

EID: 65949114287     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02709.x     Document Type: Article

References (22)

1. Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: A cross-national database study. Lancet 2005; 365: 579-587.
2. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H, European Survaillance of Antibiotic Comsuption (ESAC) Project Group. Hospital consumption of antibiotics in 15 European countries: Results of the ESAC Retrospective Data Collection (1997-2002). J Antimicrob Chemother 2006; 58: 159-167.
3. Bronzwaer SL, Cars O, Buchholz U et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002; 8: 278-282.
4. Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-607.
5. Meisner M. Pathobiochemistry and clinical use of procalcitonin. Clin Chim Acta 2002; 323: 17-29.
6. Dandona P, Nix D, Wilson MF et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79: 1605-1608.
7. Carrol ED, Thomson AP, Hart CA. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents 2002; 20: 1-9.
8. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: A systematic review and meta-analysis. Clin Infect Dis 2004; 39: 206-217.
9. Chirouze C, Schuhmacher H, Rabaud C et al. Low serum procalcitonin level accurately predicts the absence of bacteremia in adult patients with acute fever. Clin Infect Dis 2002; 35: 156-161.
10. Caterino JM, Scheatzle MD, Forbes ML, D'Antonio JA. Bacteremic elder emergency department patients: Procalcitonin and white count. Acad Emerg Med 2004; 11: 393-396.
11. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 2006; 34: 2596-2602.
12. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am J Respir Crit Care Med 2008; 177: 498-505.
13. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: Systematic review and meta-analysis. Lancet Infect Dis 2007; 7: 210-217.
14. Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: Clinical utility and limitations. Crit Care Med 2008; 36: 941-952.
15. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93.
16. Jereb M, Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr 2006; 118: 170-174.
17. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: Correlation with etiology and prognosis. Infection 2000; 28: 68-73.
18. Beovic B, Kreft S, Osredkar J, Kese D, Bonac-Tuma B. Serum procalcitonin levels in patients with mild community-acquired pneumonia. Clin Microbiol Infect 2005; 11: 1050-1051.
19. Christ-Crain M, Muller B. Procalcitonin in bacterial infections-hype, hope, more or less? Swiss Med Wkly 2005; 135: 451-460.
20. Bignardi GE, Dhar R, Heycock R, Bansal S, Majmudar N. Can procalcitonin testing reduce antibiotic prescribing for respiratory infections? Age Ageing 2006; 35: 625-626.
21. Stolz D, Christ-Crain M, Bingisser R et al. Antibiotic treatment of exacerbations of COPD: A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19.
22. el Moussaoui R, de Borgie CA, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: Randomised, double blind study. BMJ 2006; 332: 1355.